MedTrace Logo

Pembrolizumab (MK-3475) as Maintainance in Treated Patients With Unresectable Stage III NSCLC

NCT03379441 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2017-12-22

No results posted yet for this study

Summary

Maintainance therapy in patients with unresectable stage III, NSCLC Stage IIIA-B, unresectable, NSCLC, treated with definitive Chemo-Radiotherapy

Conditions

  • Non Small Cell Lung Cancer Patients

Interventions

DRUG

Pembrolizumab Injectable Product

Pembrolizumab Injectable Product 200 mg Q3W Intravenous

Sponsors & Collaborators

  • University of Turin, Italy

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2023-01-01
Completion
2023-01-01
FDA Drug
Yes

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03379441 on ClinicalTrials.gov